NEXTAGE THERAPEUTICS LTD Inactive Instrument
Nextage Therapeutics Ltd Share Price TEL AVIV STOCK EXCHANGE
Equities
NXTG
IL0004330119
Biotechnology & Medical Research
| Managers | Title | Age | Since |
|---|---|---|---|
Abraham Dreazen
CEO | Chief Executive Officer | 40 | 12/20/12 |
Ishai Gandelsman
DFI | Director of Finance/CFO | 61 | 10/22/10 |
| General Counsel | 53 | 12/20/12 |
| Members of the board | Title | Age | Since |
|---|---|---|---|
Yaacov Elinav
BRD | Director/Board Member | 79 | 12/20/12 |
Israel Makov
CHM | Chairman | 85 | 21/11/21 |
Ron Grupel
BRD | Director/Board Member | 73 | 13/14/13 |
Nextage Therapeutics Ltd, formerly known asMicromedic Technologies Ltd,is an Israel-based company engaged in the development and commercialization of cancer diagnostic products. Its portfolio includes a range of cancer and cancer-related indications including colorectal cancer, breast cancer, cervical cancer, bladder cancer, lung cancer, and diagnostic tools for personalized treatment. Micromedic forms a cluster that manages the development of a variety of products across the cancer diagnostic value chain. From screening and risk identification, through diagnostics, personalized medicine, and monitoring disease recurrence, Micromedic identifies projects that fill unmet needs in various cancer related indications, and turns them into viable marketable products. Micromedic operates through strategic collaborations and in-licensing from scientific institutes world-wide as well as in-house based research.
| 1st Jan change | Capi. | |
|---|---|---|
| -18.88% | 10.91B | |
| +53.75% | 3.3B | |
| -32.50% | 2.19B | |
| -14.31% | 2.16B | |
| -26.83% | 1.5B | |
| +28.55% | 1.09B | |
| -3.28% | 737M | |
| -23.50% | 404M | |
| -43.27% | 386M |
